R&D | Cutting-edge science and innovative research

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

News

Chinese trial backs base-editing drug for thalassaemia

A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

23andMe study explains variable results with obesity drugs

Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.

Partner Content

Partner Content

Complex Medicines: A multi-billion-pound addition to the UK ...

New report published by MDC and CPI

Views & Analysis

Taking steps towards a data-driven future for health and soc...

A new policy paper promises to make it easier for innovators and developers to build and deploy tech and AI solution.

News

Interpublic launches IPG Health

Interpublic Group has announced FCB Health and McCann Health are joining up to form a new healthcare network - IPG Health.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Chinese trial backs base-editing drug for thalassaemia

A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

pharmaphorum podcast Episode 253, Lance Baldo, Beacon Therapeutics

Looking to gene therapy for ocular diseases, with Lance Bald...

Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

Looking to gene therapy for ocular diseases, with Lance Bald...

Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

R&D

pharmaphorum podcast Episode 250, Rob DiCicco, Transcelerate

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Video

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

R&D

Interview at BIO-Europe 2026 with Robert Jacks

BIO-Europe Spring 2026: In conversation with Robert Jacks

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

White Papers

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Event

Partner Content

PHARMAP 2026: From Vendors to Strategic Partners

Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs

Event

Partner Content

6th mRNA‑Based Therapeutics Summit

Advancing mRNA's Therapeutic Potential to Combat All Diseases

Event

Partner Content

The Industry’s Most Comprehensive End-to-End TCE Forum

The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,

Partner Content

Event

Partner Content

PHARMAP 2026: From Vendors to Strategic Partners

Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs

Event

Partner Content

6th mRNA‑Based Therapeutics Summit

Advancing mRNA's Therapeutic Potential to Combat All Diseases

Event

Partner Content

The Industry’s Most Comprehensive End-to-End TCE Forum

The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,

Changing Faces: Pharma and biotech, March 2026

Chinese trial backs base-editing drug for thalassaemia

Roche places a $1bn bet on C4T degrader-antibody conjugates

Pulmonary fibrosis drug developer Avalyn files IPO

23andMe study explains variable results with obesity drugs

Complex Medicines: A multi-billion-pound addition to the UK ...

Taking steps towards a data-driven future for health and soc...

Interpublic launches IPG Health

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

Chinese trial backs base-editing drug for thalassaemia

Roche places a $1bn bet on C4T degrader-antibody conjugates

Touring Chiesi's vision for the future at the new Biotech Ce...

Vir awarded $1 billion multi-year BARDA influenza contract

Changing Faces: Pharma and biotech, March 2026

A data-driven guide to small molecule drug discovery and dev...

Looking to gene therapy for ocular diseases, with Lance Bald...

The GLP-1 Reckoning

Designing obesity trials around real lives: How patient cent...

Beyond obesity: How GLP-1s are changing the game for hundred...

Exploring the future: Opportunities and challenges in cell a...

Beyond clinical: Boosting recruitment and retention with SDO...

The evolution of clinical research: Embracing new delivery m...

Looking to gene therapy for ocular diseases, with Lance Bald...

Making AI work where it matters, with Rob DiCicco

Treating genetic disease at scale with tRNA, with Michelle W...

LSX2026: On a therapeutic vision for ocular disease, with Al...

BIO-Europe Spring 2026: In conversation with Robert Jacks

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

A data-driven guide to small molecule drug discovery and dev...

A New Framework to Engineer Breakthrough Value for Medicines

Life Sciences Industry Report - Biologics and Generics

PHARMAP 2026: From Vendors to Strategic Partners

6th mRNA‑Based Therapeutics Summit

The Industry’s Most Comprehensive End-to-End TCE Forum

PHARMAP 2026: From Vendors to Strategic Partners

6th mRNA‑Based Therapeutics Summit

The Industry’s Most Comprehensive End-to-End TCE Forum

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks